- Sarepta Therapeutics (SRPT +0.8%) bucks biotech's down day on average volume. On CNBC, hedge fund manage Joe Edelman re-emphasized his confidence that DMD candidate eteplirsen will be approved by the FDA.
- The Ad Comm review is scheduled for April 25 followed by the PDUFA date on May 26.
- This is a superb example of the prominence (risk) of a binary event for biotech investors. It will be either feast or famine. BioMarin Pharmaceutical (BMRN -0.4%) longs felt the sting of rejection a few months ago with its DMD candidate drisapersen.
- Previously: FDA rejects BioMarin's drisapersen for Duchenne muscular dystrophy (Jan. 14)
- Previously: Ad Comm fails to back BioMarin's drisapersen for DMD (Nov. 24, 2015)
Sarepta gets modest bump from Edelman's bullish comments on CNBC; shares up 1%
Recommended For You
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |